APUS — Apimeds Pharmaceuticals US Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Apimeds Pharmaceuticals US, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.02 | 0.64 | 0.747 | 1.28 | 5.9 |
| Operating Profit | -1.02 | -0.64 | -0.747 | -1.28 | -5.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.03 | -0.669 | -0.778 | -1.39 | -6 |
| Net Income After Taxes | -1.03 | -0.669 | -0.778 | -1.39 | -6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.03 | -0.669 | -0.778 | -1.39 | -6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.03 | -0.669 | -0.778 | -1.39 | -6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.887 | -0.578 | -0.067 | -1.2 | -1.1 |
| Dividends per Share |